



26 October 2021

**Clinical Study Protocol**

**TL-895-202**

**EudraCT Number: 2020-002259-39**

**A Phase 1/2, Double-Blind, Randomized, Placebo- Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer**

This study was submitted and approved by the authorities; however, there were no patients enrolled in the European economic area; therefore, no report was created.

DocuSigned by:

*John Mei*



Signer Name: John Mei

Signing Reason: I approve this document

Signing Time: 26-Oct-2021 | 11:01 AM PDT

4816A4E1650247EE8DF52D79A657AB28

---

John H M Mei

VP, Clinical Operations  
Telios Pharma